Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
November 23 2021 - 7:00AM
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage
biopharmaceutical company pursuing novel therapeutics for
cardio-metabolic and fatty liver diseases with high unmet medical
need such as non-alcoholic steatohepatitis (NASH), announced today
its management team will participate in two upcoming virtual
investor conferences:
Evercore ISI 4th Annual HealthCONx Conference
2021
Fireside chat at 9:40 AM EST on Tuesday, November 30, 2021
Piper Sandler 33rd Annual Virtual Healthcare
Conference
Fireside chat at 11:30 AM EST on Thursday, December 2, 2021
The presentations will be webcast live and archived recordings
will be available for replay in the Events & Presentations
section of the Madrigal website for 90 days following the live
presentations.
About Madrigal PharmaceuticalsMadrigal
Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage
biopharmaceutical company pursuing novel therapeutics that target a
specific thyroid hormone receptor pathway in the liver, which is a
key regulatory mechanism common to a spectrum of fatty liver and
cardio-metabolic diseases with high unmet medical need. Madrigal’s
lead candidate, resmetirom, is a first-in-class, orally
administered, small-molecule, liver-directed, thyroid hormone
receptor (THR)-β selective agonist that is currently in two Phase 3
clinical studies, MAESTRO-NASH and MAESTRO- NAFLD-1, designed to
demonstrate multiple benefits in NASH (non-alcoholic
steatohepatitis) patients. For more information, visit
www.madrigalpharma.com.
Investor Contact Alex Howarth, Madrigal
Pharmaceuticals, Inc., IR@madrigalpharma.com
Media ContactChristopher Frates, Madrigal
Pharmaceuticals, Inc., media@madrigalpharma.com
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Madrigal Pharmaceuticals (NASDAQ:MDGL)
Historical Stock Chart
From Apr 2023 to Apr 2024